Given the high proportion of APOE4 carriers in the AD population and the strong pathogenic effects of APOE4, it is crucial to devise safe therapeutic strategies for this population, particularly E4/E4 subjects [180, 222, 223]. The gene discussed is APOE; the disease is Alzheimer disease.